SWK Holdings Corp
For the period ended Nov 6, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 6, 2025 · Filed Nov 6, 2025
Use the contents to explore the available documents and sections.
SWKHL$25.21+0.1%Stored close · as of Nov 2, 2026
Contents
EX-99.1 · (in thousands, except per share data)
(in thousands, except per share data)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenues: | ||||
| Finance receivable interest income, including fees | $10,822 | $9,498 | $30,077 | $30,519 |
| Pharmaceutical development | — | 628 | 2,153 | 1,711 |
| Other | 60 | 292 | 536 | 395 |
| Total revenues | 10,882 | 10,418 | 32,766 | 32,625 |
| Costs and expenses: | ||||
| Provision (benefit) for credit losses | (931) | 1,385 | (1,635) | 10,777 |
| Loss on impairment of intangibles assets | 209 | — | 209 | 5,771 |
| Loss on disposal of inventory | 314 | — | 314 | — |
| Interest expense | 1,179 | 1,139 | 3,464 | 3,514 |
| Pharmaceutical manufacturing, research and development expense | 147 | 585 | 1,550 | 1,635 |
| Change in fair value of acquisition-related contingent consideration | — | — | — | (4,900) |
| Depreciation and amortization expense | 2 | 234 | 40 | 1,169 |
| General and administrative expense | 3,286 | 2,993 | 9,406 | 8,597 |
| Income from operations | 6,676 | 4,082 | 19,418 | 6,062 |
| Other income (expense), net | ||||
| Unrealized net loss on warrants | 2,640 | 47 | 2,563 | 178 |
| Net loss on exercise and cancellation of warrants | — | — | — | 444 |
| Net loss on marketable investments | (246) | (6) | (314) | (168) |
| Loss on sale of assets | — | — | (82) | — |
| Gain on sale of business | 1,601 | — | 1,601 | — |
| Realized gain on early payment of finance receivable | — | — | 1,729 | — |
| Gain (loss) on revaluation of finance receivables | — | — | (3,727) | 2,495 |
| Realized and unrealized foreign currency transaction gains (losses) | 25 | 251 | (113) | 775 |
| Income before income tax expense | 10,696 | 4,374 | 21,075 | 9,786 |
| Income tax expense | 1,916 | 906 | 4,220 | 2,170 |
| Net income | $8,780 | $3,468 | $16,855 | $7,616 |
| Net income per share | ||||
| Basic | $0.72 | $0.28 | $1.38 | $0.61 |
| Diluted | $0.72 | $0.28 | $1.38 | $0.61 |
| Weighted average shares outstanding | ||||
| Basic | 12,117 | 12,318 | 12,184 | 12,417 |
| Diluted | 12,117 | 12,408 | 12,184 | 12,492 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.